



January 11, 2024

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051

**Scrip code: 532531**

**Scrip code: STAR**

Dear Madam/ Sir,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/ HO/ CFD/ CFD-PoD-1/ P/ CIR/ 2023/ 123 dated July 13, 2023**

---

This is to inform you that as part of entity optimization exercise, Fairmed Healthcare AG, Switzerland, a step-down subsidiary of the Company in Switzerland, has entered into a Share Purchase Agreement dated January 9, 2024, for divestment of its 100% shareholding in Eris Pharma GmbH, Germany (Eris) to a third party.

Disclosure under Regulation 30 of SEBI Listing Regulations read with SEBI Circular dated July 13, 2023 relating to the proposed transaction is enclosed.

This is for your information and records.

Thanks & Regards,  
For **Strides Pharma Science Limited**,

**Manjula Ramamurthy**  
Company Secretary  
ICSI Membership No. A30515



*Encl. As above*

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700  
Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

**Disclosure under Regulation 30 of the Securities and Exchange Board of India  
(Listing Obligations and Disclosure Requirements) Regulation, 2015 read with  
SEBI/ HO/ CFD/ CFD-PoD-1/ P/ CIR/ 2023/ 123 dated July 13, 2023**

**Divestment of 100% stake in Eris Pharma GmbH, Germany  
by Fairmed Healthcare AG, Switzerland, a step-down subsidiary of the Company**

#	Particulars	Remarks
a)	Amount and percentage of Turnover or Revenue or Income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	The transaction relates to sale of 100% shareholding held in Eris Pharma GmbH, Germany (Eris) by Fairmed Healthcare AG, Switzerland (Fairmed), a step-down subsidiary of the Company.  Eris' revenue for FY23 was ~Euro 5,062 and had a negative network.
b)	Date on which Agreement for Sale has been entered into	January 9, 2024
c)	Expected Date of Completion of Sale/ Disposal	Closing shall take place on or before January 31, 2024 OR any other date as mutually agreed between the parties.
d)	Consideration received from such Sale/ Disposal	Euro 200,000
e)	Brief details of Buyers and  Whether any of the Buyers belong to Promoter/ Promoter Group/ Group companies.  If yes, details thereof	Maxmind Pharmaceutical SL having its registered office at Calle Copenhagen 12, Oficina 205, Edificio Tifan, Las Rozas de Madrid 28232, Spain.  Buyer is not related to any of the Promoter/ Promoter Group/ Group Companies of Strides.
f)	Whether transaction would fall within Related Party Transactions?  If yes, whether the same is done at "Arms' length";	No



**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

g)	<p>Whether sale, lease or disposal of the undertaking is outside Scheme of Arrangement?</p> <p>If yes, details of the same including compliance with regulation 37A of LODR Regulations</p>	Not Applicable
h)	<p>Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to such slump sale.</p> <p><i>For the purpose of this sub-clause, "slump sale" shall mean the transfer of one or more undertakings, as a result of the sale for a lump sum consideration, without values being assigned to the individual assets and liabilities in such sales.</i></p>	Not Applicable
i)	Reason for delay in intimation	<p>While the Company had sought certain clarifications from the concerned parties, receipt of such clarification was delayed.</p> <p>Consequently, intimation for this transaction to Stock Exchanges is delayed by one day.</p>

\*\*\*\*\*



**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com